BTK Inhibitors as Sensitizing Agents in Solid Tumors

About

Robert Dreicer MD MS FASCO MACP received his medical degree from the University of Texas-Houston and a Master of Science from the University of Texas Graduate School of Biomedical Sciences. Following his oncology fellowship he joined the faculty at University of Iowa achieving tenure and serving as the associate director of the division of haematology/oncology. He was recruited to Cleveland Clinic where he served as chair of the department of solid tumor oncology from 2006-2014 before joining UVA Cancer Center in 2015. His research interests are in novel therapeutic approaches for urologic cancer including prostate urothelial and kidney cancers. He serves as member of the Medical Oncology Test Writing Committee of the American Board of Internal Medicine and is member of the editorial board of New England Journal of Medicine's Journal Watch Hematology/Oncology. Dreicer has been named for many years to Top Doctors in America Americas Best Doctors and Americas Top Doctors for Cancer. Dr Varinder Kaur MD FACP has expertise in haematology and medical oncology including clinical application of ibrutinib in its varied roles. She is a clinical trialist at University of Virginia with particular focus on melanoma and head-neck cancers immune-oncology and vaccine trials. She has authored several high-quality publications including with rare side effects and resistance mechanisms for ibrutinib. She mentors clinical fellows and residents. She is a member of scientific review committee of Oncology Research Information Exchange Network and has reviewed grant applications for the same. She has served as a member for American Society of Clinical Oncology Systemic Therapy guidelines for melanoma committee and ASCO/ABIM test material development subcommittee as well as a member of ASCO Education Book Review Panel. Dr. Al-Ola Abdallah MD is currently Assistant Professor of Medicine and the director of the Plasma Cell Disorder Clinic for the Division of Hematological Malignancies and Cellular Therapy (HMCT). Recently he was also appointed as the Educational Medical Director for the Division. Dr. Abdallah currently works as principal investigator on many investigator-initiated and pharmaceutical-sponsored clinical trials. His research interests include multiple myeloma smoldering myeloma amyloidosis immunotherapy and CAR-T cell for myeloma and CLL with a focus on improving patient outcomes specifically patients with high-risk subsets of plasma cell dyscrasias and health- related quality of life in myeloma patients.